Reductions in Serum Lipids with a 4-year Decline in Serum Perfluorooctanoic Acid and Perfluorooctanesulfonic Acid

Background: Several epidemiological cross-sectional studies have found positive associations between serum concentrations of lipids and perfluorooctanoic acid (PFOA, or C8). A longitudinal study should be less susceptible to biases from uncontrolled confounding or reverse causality. Methods: We investigated the association between within-individual changes in serum PFOA and perfluorooctanesulfonic acid (PFOS) and changes in serum lipid levels (low-density lipoprotein [LDL] cholesterol, high-density lipoprotein cholesterol, total cholesterol, and triglycerides) over a 4.4-year period. The study population consisted of 560 adults living in parts of Ohio and West Virginia where public drinking water had been contaminated with PFOA. They had participated in a cross-sectional study in 2005–2006, and were followed up in 2010, by which time exposure to PFOA had been substantially reduced. Results: Overall serum concentrations of PFOA and PFOS fell by half from initial geometric means of 74.8 and 18.5 ng/mL, respectively, with little corresponding change in LDL cholesterol (mean increase 1.8%, standard deviation 26.6%). However, there was a tendency for people with greater declines in serum PFOA or PFOS to have greater LDL decrease. For a person whose serum PFOA fell by half, the predicted fall in LDL cholesterol was 3.6% (95% confidence interval = 1.5–5.7%). The association with a decline in PFOS was even stronger, with a 5% decrease in LDL (2.5–7.4%). Conclusions: Our findings from this longitudinal study support previous evidence from cross-sectional studies of positive associations between PFOA and PFOS in serum and LDL cholesterol.

[1]  Jiayin Dai,et al.  Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. , 2012, Environmental science & technology.

[2]  G. Olsen,et al.  Longitudinal Assessment of Lipid and Hepatic Clinical Parameters in Workers Involved With the Demolition of Perfluoroalkyl Manufacturing Facilities , 2012, Journal of occupational and environmental medicine.

[3]  A. Calafat,et al.  Improved selectivity for the analysis of maternal serum and cord serum for polyfluoroalkyl chemicals. , 2011, Journal of chromatography. A.

[4]  A. Calafat,et al.  Trends in exposure to polyfluoroalkyl chemicals in the U.S. Population: 1999-2008. , 2011, Environmental science & technology.

[5]  B. Sanders,et al.  Environmental fate and transport modeling for perfluorooctanoic acid emitted from the Washington Works Facility in West Virginia. , 2011, Environmental science & technology.

[6]  J. M. Keller,et al.  Determination of perfluorinated alkyl acid concentrations in human serum and milk standard reference materials , 2010, Analytical and bioanalytical chemistry.

[7]  D. Savitz,et al.  Epidemiologic Evidence on the Health Effects of Perfluorooctanoic Acid (PFOA) , 2010, Environmental health perspectives.

[8]  V. Vaccarino,et al.  Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. , 2009, American journal of epidemiology.

[9]  A. Calafat,et al.  Rate of Decline in Serum PFOA Concentrations after Granular Activated Carbon Filtration at Two Public Water Systems in Ohio and West Virginia , 2009, Environmental health perspectives.

[10]  Tony Fletcher,et al.  The C8 Health Project: Design, Methods, and Participants , 2009, Environmental health perspectives.

[11]  D. Consonni,et al.  Thirty Years of Medical Surveillance in Perfluooctanoic Acid Production Workers , 2009, Journal of occupational and environmental medicine.

[12]  B. Staels,et al.  Regulation of Macrophage Functions by PPAR-&agr;, PPAR-&ggr;, and LXRs in Mice and Men , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[13]  John W Green,et al.  Cross-Sectional Study of Lipids and Liver Enzymes Related to a Serum Biomarker of Exposure (ammonium perfluorooctanoate or APFO) as Part of a General Health Survey in a Cohort of Occupationally Exposed Workers , 2007, Journal of occupational and environmental medicine.

[14]  C. Lau,et al.  Perfluoroalkyl acids: a review of monitoring and toxicological findings. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  Mark R Cullen,et al.  Longitudinal Study of Serum Lipids and Liver Enzymes in Workers With Occupational Exposure to Ammonium Perfluorooctanoate , 2007, Journal of occupational and environmental medicine.

[16]  Alan Y. Chiang,et al.  Generalized Additive Models: An Introduction With R , 2007, Technometrics.

[17]  Geary W Olsen,et al.  Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers , 2007, International archives of occupational and environmental health.

[18]  John W. Froehlich,et al.  Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers , 2007, Environmental health perspectives.

[19]  Kellyn S. Betts,et al.  PERFLUOROALKYL ACIDS: What Is the Evidence Telling Us? , 2007, Environmental health perspectives.

[20]  J. Plutzky,et al.  Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. , 2007, Circulation.

[21]  J. Boer,et al.  Struggle for quality in determination of perfluorinated contaminants in environmental and human samples. , 2006 .

[22]  L. Shaw,et al.  Community Exposure to Perfluorooctanoate: Relationships Between Serum Levels and Certain Health Parameters , 2006, Journal of occupational and environmental medicine.

[23]  John P. Vanden Heuvel,et al.  Differential Activation of Nuclear Receptors by Perfluorinated Fatty Acid Analogs and Natural Fatty Acids: A Comparison of Human, Mouse, and Rat Peroxisome Proliferator-Activated Receptor-α, -β, and -γ, Liver X Receptor-β, and Retinoid X Receptor-α , 2006 .

[24]  Edsel A. Peña,et al.  Global Validation of Linear Model Assumptions , 2006, Journal of the American Statistical Association.

[25]  J. Grego,et al.  Fast stable direct fitting and smoothness selection for generalized additive models , 2006, 0709.3906.

[26]  D. Jacobs,et al.  Twenty-Year Trends in Serum Cholesterol, Hypercholesterolemia, and Cholesterol Medication Use: The Minnesota Heart Survey, 1980–1982 to 2000–2002 , 2005, Circulation.

[27]  J. Robins,et al.  When is baseline adjustment useful in analyses of change? An example with education and cognitive change. , 2005, American journal of epidemiology.

[28]  Roger G Perkins,et al.  The Toxicology of Perfluorooctanoate , 2004, Critical reviews in toxicology.

[29]  Qian Yang,et al.  The relationship between liver peroxisome proliferation and adipose tissue atrophy induced by peroxisome proliferator exposure and withdrawal in mice. , 2003, Biochemical pharmacology.

[30]  Jeffrey H Mandel,et al.  Epidemiologic Assessment of Worker Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Concentrations and Medical Surveillance Examinations , 2003, Journal of occupational and environmental medicine.

[31]  J. Mandel,et al.  PLASMA CHOLECYSTOKININ AND HEPATIC ENZYMES, CHOLESTEROL AND LIPOPROTEINS IN AMMONIUM PERFLUOROOCTANOATE PRODUCTION WORKERS , 2000, Drug and chemical toxicology.

[32]  David J. Waxman,et al.  trans-activation of PPARα and PPARγ by structurally diverse environmental chemicals , 1999 .

[33]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[34]  J. A. Calvin.  Regression Models for Categorical and Limited Dependent Variables , 1998 .

[35]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[36]  J. S. Long,et al.  Regression Models for Categorical and Limited Dependent Variables , 1997 .

[37]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[38]  Jeffrey K. Liker,et al.  Panel Data and Models of Change: A Comparison of First Difference and Conventional Two-Wave Models , 1985 .

[39]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[40]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[41]  B. Abbott,et al.  Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors ( , / , ) by Perfluorooctanoic Acid and Perfluorooctane Sulfonate , 2006 .

[42]  E. K. Maloney,et al.  trans-Activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. , 1999, Toxicology and applied pharmacology.